Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,742.39
(
0.64%
)
US TECH 100
24,182.80
(
0.70%
)
Dow Jones
47,203.22
(
0.55%
)
Brent Oil
99.02
(
0.73%
)
Bitcoin
74,230.46
(
-0.82%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 48555

Friday, 06/15/2007 12:37:23 PM

Friday, June 15, 2007 12:37:23 PM

Post# of 257251
Re: Lotrel patent case

It sounds like the court’s interpretation of the formulation claims in NVS’ patent could go either way. For this reason, I would expect Teva to argue at the trial that the method-of-use claims in NVS’ patent are unenforceable due to obviousness. Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now